Crystalline form of glp-1 receptor agonist and preparation method therefor

Crystal form A, B1, B2, B3, C, D, E, F or G of compound 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid,

• wherein (1) an X-ray powder diffraction pattern of the crystal form A expressed with diffraction angle 2θ has characteristic peaks at 9.587, 10.216, 11.812, 18.204, and 23.404;
• (2) an X-ray powder diffraction pattern of the crystal form B1 expressed with diffraction angle 2θ has characteristic peaks at 8.135, 8.915, 11.259, 11.508, 19.024, and 25.271;
• (3) an X-ray powder diffraction pattern of the crystal form B2 expressed with diffraction angle 2θ has characteristic peaks at 8.182, 8.839, 10.401, 11.168, and 18.906;
• (4) an X-ray powder diffraction pattern of the crystal form B3 expressed with diffraction angle 2θ has characteristic peaks at 10.548, 11.496, 17.557, 19.135, 19.751, and 25.360:
• (5) an X-ray powder diffraction pattern of the crystal form C expressed with diffraction angle 2θ has characteristic peaks at 10.094, 11.511, 17.378, and 20.113:
• (6) an X-ray powder diffraction pattern of the crystal form D expressed with diffraction angle 2θ has characteristic peaks at 10.940, 12.216, 18.344, 19.931, and 22.979:
• (7) an X-ray powder diffraction pattern of the crystal form E expressed with diffraction angle 2θ has characteristic peaks at 11.591, 17.645, 19.060, 20.066, 20.667, and 26.987:
• (8) an X-ray powder diffraction pattern of the crystal form F expressed with diffraction angle 2θ has characteristic peaks at 9.543, 19.405, and 22.153;
• and
• (9) an X-ray powder diffraction pattern of the crystal form G expressed with diffraction angle 2θ has characteristic peaks at 9.096, 11.107, 17.239, and 17.744.